The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | COCOON: dermatologic management with amivantamab & lazertinib
Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, South Korea, comments on the dermatologic management of amivantamab and lazertinib in the Phase II COCOON trial (NCT06120140). In patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), the prophylactic regimen significantly reduced the incidence of moderate-to-severe dermatologic adverse events compared with standard care, particularly for face/body and scalp reactions, without compromising efficacy. Quality of life was also improved with the enhanced regimen. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In my first study, first-line amivantamab plus lazertinib significantly improved PFS and OS compared to osimertinib in advanced stage EGFR mutant lung cancer. Consistent with other EGFR target therapy, amivantamab plus lazertinib is associated with EGFR-related skin rash which are mostly grade 1 or 2 and occurs within 4 months of treatment. Cocoon study was conducted to evaluate whether enhanced dermatology management or Cocoon-DEM could reduce dermatologic adverse event in patients receiving first-line amivantamab plus lazertinib...
In my first study, first-line amivantamab plus lazertinib significantly improved PFS and OS compared to osimertinib in advanced stage EGFR mutant lung cancer. Consistent with other EGFR target therapy, amivantamab plus lazertinib is associated with EGFR-related skin rash which are mostly grade 1 or 2 and occurs within 4 months of treatment. Cocoon study was conducted to evaluate whether enhanced dermatology management or Cocoon-DEM could reduce dermatologic adverse event in patients receiving first-line amivantamab plus lazertinib. So in the Cocoon study, Cocoon-DEM significantly reduced grade 2 or higher dermatologic adverse event compared to standard care in patients receiving first-line amivantamab plus lazertinib. Progression-free survival was comparable between two arms, and the benefit with Cocoon-DEM was consistent across different skin sites. We also looked at patient-reported outcome, and then Cocoon-DEM was associated with improved quality of life and reduced dermatologic symptom compared to standard care in patients receiving first-line amivantamab plus lazertinib. Objective response rate was comparable between two arms, which suggests that Cocoon-DEM did not alter anti-tumor activity of amivantamab plus lazertinib. Treatment modification and discontinuation of Cocoon-DEM was rare and uncommon and the effect of Cocoon-DEM was maintained even after discontinuation of oral antibiotics. So in conclusion Cocoon-DEM significantly reduced grade 2 or higher incidence of dermatology adverse event related to first-line amivantamab plus lazertinib compared to standard care and it also significantly improved patient quality of life and reduced dermatologic symptoms associated with this treatment. So since amivantamab plus lazertinib produce clinically meaningful overall survival benefit compared to osimertinib and Cocoon-DEM further enhance improved risk to benefit profile of this treatment. MARPIPOSA along with the Cocoon-DEM regimen can be standard care in treatment for EGFR mutant advanced stage NSCLC patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
